Effect of oral methylprednisolone mini-pulse with oral tofacitinib and oral methylprednisolone mini-pulse with oral azathioprine in treatment of progressive non- segmental vitiligo

Comparison of the efficacy and safety of oral methylprednisolone mini-pulse with oral tofacitinib and oral methylprednisolone mini-pulse with oral azathioprine in treatment of progressive non- segmental vitiligo: A Randomized Controlled Trial - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/077078

Enrollment

142

Registered

2024-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: methylprednisolone and tofacitinib: oral methylprednisolone 32 mg on two consecutive days every week and oral tofacitinib 5 mg twice daily for 6 months Control Intervention1: methylpred

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed cases of progressive non-segmental vitiligo with affected body surface area equals to or more than 5% 2.Age: 18 to 65 years 3. Patients not taking systemic drug in last 1 month and topical treatment in last 15 days 4. All participants who give consent for the study

Exclusion criteria

Exclusion criteria: 1. Patients having history or active tuberculosis. 2. Patients with pregnancy and lactating mother. 3. Patients with uncontrolled renal, hepatic, hematological or heart disease.

Design outcomes

Primary

Measure	Time frame
Reduction in Vitiligo Area Severity Index (VASI) by 75%Timepoint: Reduction in Vitiligo Area Severity Index (VASI) by 75% which will be assessed monthly for 6 months	—

Secondary

Measure	Time frame
Reduction in Vitiligo Area Severity Index (VASI) by 50% and reduction in Vitiligo Area Severity Index (VASI) by 100%Timepoint: Reduction in Vitiligo Area Severity Index (VASI) by 50% and reduction in Vitiligo Area Severity Index (VASI) by 100% which will be assessed monthly for 6 months	—

Countries

India

Contacts

Public ContactDr Annu Saini

Institute of Medical Sciences Banaras Hindu University

drsatyendraderma@gmail.com9198120582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026